1. US Food and Drug Administration FDA public health advisory: updated safety information about Raptiva (efalizumab) [
online
] (2009).
2. US Food and Drug Administration FDA approves updated labeling for psoriasis drug Raptiva: safety concerns drove labeling change [
online
] (2009).
3. Calabrese, L. H., Molloy, E. S., Huang, D. & Ransohoff, R. M. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 56, 2116–2128 (2007).
4. Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun. Rev. 8, 144–146 (2008).
5. Calabrese, L. H. & Molloy, E. S. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann. Rheum. Dis. 67 (Suppl. 3), iii64–iii65 (2008).